![Todd Bazemore](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Todd Bazemore
Direktor/Vorstandsmitglied bei
PULMATRIX, INC.
Vermögen: 647 $ am 31.05.2026
Profil
Todd Bazemore is President, Chief Executive Officer & Director at Airna, Inc. since 2026.
Mr. Bazemore is Independent Director at Pulmatrix, Inc. since 2020.
Former positions include Director at Kala Bio, Inc. from 2025 to 2026; Vice President-Managed Markets at Sumitomo Pharma America, Inc. from 2012 to 2013; Chief Commercial Officer & Executive Vice President at Dyax Corp.
from 2014 to 2016; Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals Holding AG from 2016 to 2017; and Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals (USA), Inc. from 2016 to 2017.
Education includes undergraduate studies at the University of Massachusetts Lowell.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.12.2025 | 290 ( 0 % ) | 647 $ | 31.05.2026 | |
PULMATRIX INC -.--% | 23.02.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Todd Bazemore
| Unternehmen | Position | Beginn |
|---|---|---|
| PULMATRIX, INC. | Direktor/Vorstandsmitglied | 01.10.2020 |
Airna, Inc.
 Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Vorstandsvorsitzender | 02.06.2026 |
Ehemalige bekannte Positionen von Todd Bazemore
| Unternehmen | Position | Ende |
|---|---|---|
| KALA BIO, INC. | Vorstandsvorsitzender | 23.11.2025 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Geschäftsführer | 01.11.2017 |
Santhera Pharmaceuticals (USA), Inc.
 Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Geschäftsführer | 01.11.2017 |
| DYAX CORP. | Corporate Officer/Principal | 22.01.2016 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01.09.2013 |
Ausbildung von Todd Bazemore
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
30
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Dyax Corp.
 Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
Kala Bio, Inc.
 Kala Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing mesenchymal stem cell secretive (MSC-S) therapies | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Massachusetts Lowell
 University of Massachusetts Lowell Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pulmatrix, Inc.
 Pulmatrix, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for pulmonary disease | Health Technology |
Santhera Pharmaceuticals (USA), Inc.
Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Health Technology |
Airna, Inc.
Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Commercial Services |
